- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Precision Medicine, the Oncology Care Model, and PD-1s
The third segment of The Clinical and Reimbursement Landscape of Immuno-Oncology series, focusing on the new PD-1 agents, addressed personalized or precision medicine and CMMI’s new Oncology Care Model. Dr Kolodziej, an Aetna national medical director of oncology strategy, believes that precision medicine is not a perfect fit for the new model, but at least partially it can be paid for through “innovation” payments. He points out that precision medicine should not evolve greatly within the timeframe of the Oncology Care Model (3-5 yr), so it should not have a great deal of effect on the success of the model.
The PD-1 class, although very much part of the precision medicine treatment concept, “which kind of throws it all on its head,” says Dr Feinberg, Cardinal Health Specialty Solutions vice president and chief medical officer. Instead of identifying unique molecular and genetic phenomenon occurring in individual tumors, PD-1s may be active against “half or two-thirds of all malignancies,” not a tiny proportion of a population with a particular cancer.
Dr Feinberg emphasizes that the mechanism of action of PD-1 agents to abort tumor growth applies to a majority of tumor types. He comments, “It’s personalized, precision medicine that may be precision for everyone.”
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More
